Gwinnett Clinical Research Center, Inc   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Snellville GA United States (1981)

Organization Overview

First Clinical Trial
2010
NCT01188928
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Gwinnett Clinical Research Center, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erythema (Phase 3)

Keratosis (Phase 2)

Keratosis, Actinic (Phase 2)

Keratosis, Seborrheic (Phase 2)

Psoriasis (Phase 3)

Rosacea (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5